Traws Pharma (TRAW) AI Stock Analysis

• Market Cap: $10.15M
• Dividend Yield: N/A
• Average Volume (3M): 206.36K
• Price to Earnings (P/E): <0.1
• Beta (1Y): 0.63
• Revenue Growth: 1159.29%
• EPS Growth: N/A
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 7,990,867
• 10 Day Avg. Volume: 403,079
• 30 Day Avg. Volume: 206,356
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.44
• Price to Sales (P/S): 61.01
• P/FCF Ratio: -0.46
• Enterprise Value/Market Cap: -0.44
• Enterprise Value/Revenue: -1.60
• Enterprise Value/Gross Profit: -1.60
• Enterprise Value/Ebitda: 0.41
• 1Y Price Target: $8.00
• Price Target Upside: 529.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $2.00 ▲(57.48% Upside)

The score is held back primarily by weak financial performance—minimal revenue, rapidly expanding losses, negative equity, and rising cash burn—implying elevated funding risk. Technicals are mixed (short-term improvement but longer-term pressure), while corporate events provide a partial offset due to positive clinical/regulatory momentum. Valuation signals are limited given the loss-making profile and lack of dividend data.

Positive Factors

Pipeline clinical progress

Filing an IND for TXM and positive Phase 2 ratutrelvir results are structural de-risking milestones that increase regulatory and commercial optionality. These advances raise the probability of future approval, BARDA consideration for stockpile inclusion, and strategic partner interest over the coming months.

Differentiated antiviral profile

A ritonavir-free oral protease inhibitor with fewer interactions and no observed rebound events provides durable clinical differentiation, expanding eligible patient pools and lowering prescribing barriers. This structural product advantage can help capture market share and support longer-term adoption if later-stage trials confirm benefit.

No debt on balance sheet

Absence of debt reduces fixed financing costs and bankruptcy risk, preserving cash flow flexibility during costly clinical development. Over a multi-quarter horizon this lowers insolvency risk versus highly leveraged peers and improves attractiveness to partners or acquirers seeking cleaner balance sheets.

Negative Factors

High and growing cash burn

Sustained and accelerating negative operating cash flow indicates the company will need external financing within months. This creates dilution or partnership dependency risk, constrains discretionary R&D and commercialization investments, and elevates execution risk absent firm funding plans.

Widening losses with immaterial revenue

Sharp loss expansion against an immaterial revenue base underscores pre-commercial status and limited internal ability to self-fund growth. Persistently negative profitability reduces strategic options, forcing reliance on capital markets or partnerships and increasing dilution risk for shareholders.

Negative equity and small asset base

Negative equity and a small asset base reflect accumulated losses and thin balance-sheet cushions. This weakens borrowing capacity, limits negotiating leverage with licensors or partners, and raises the probability of dilutive financings or asset sales to sustain development programs over the medium term.

Traws Pharma Business Overview & Revenue Model

Company Description

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

How the Company Makes Money

Traws Pharma generates revenue primarily through the sale of its pharmaceutical products and therapies that have gained regulatory approval. The company also engages in licensing agreements, where it grants other pharmaceutical firms access to its proprietary technologies and compounds in exchange for upfront payments, milestone fees, and royalties on sales. Additionally, Traws Pharma may receive funding from research grants and collaborations with academic institutions or other industry players. Strategic partnerships with larger pharmaceutical companies also contribute to its earnings, facilitating the co-development and co-promotion of new therapies.

Traws Pharma Financial Statement Overview

Summary

Traws Pharma faces significant financial challenges with persistent losses, negative equity, and reliance on external financing. The lack of revenue growth and profitability highlights the need for strategic changes to improve financial health.

Income Statement

Traws Pharma's income statement reveals persistent losses over the years, with no revenue growth and negative EBIT and EBITDA margins. The net profit margin is consistently negative, indicating ongoing profitability challenges.

Balance Sheet

The balance sheet shows negative stockholders' equity, indicating financial distress. The equity ratio is negative due to liabilities exceeding assets, and there is no debt, which mitigates risk but also highlights the lack of financial leverage.

Cash Flow

Cash flow analysis indicates negative free cash flow and operating cash flow, with an inability to cover operating expenses. The company relies heavily on financing activities to sustain operations, which is unsustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.79M	226.00K	226.00K	226.00K	226.00K	231.00K
Gross Profit	2.79M	214.00K	226.00K	226.00K	226.00K	231.00K
EBITDA	-10.97M	-166.51M	-20.28M	-19.61M	-16.48M	-24.98M
Net Income	-9.10M	-54.67M	-18.95M	-18.96M	-16.16M	-25.16M
Balance Sheet
Total Assets	15.62M	24.96M	22.68M	39.37M	55.48M	19.99M
Cash, Cash Equivalents and Short-Term Investments	13.08M	21.34M	20.82M	38.76M	55.07M	19.02M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	7.36M	56.59M	12.01M	11.06M	9.36M	13.81M
Stockholders Equity	8.26M	-31.63M	10.67M	28.31M	46.12M	6.17M
Cash Flow
Free Cash Flow	-10.02M	-29.79M	-17.95M	-16.29M	-19.49M	-23.09M
Operating Cash Flow	-10.02M	-29.79M	-17.93M	-16.29M	-19.49M	-23.07M
Investing Cash Flow	0.00	-3.65M	-14.00K	0.00	0.00	-15.00K
Financing Cash Flow	23.07M	33.98M	0.00	0.00	55.56M	19.36M

Traws Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Neutral. The current price of 1.27 is below the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.88, and below the 200-day MA of 1.80, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 56.09 is Neutral, neither overbought nor oversold. The STOCH value of 78.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRAW.

Traws Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APLM	52 Neutral	$24.00M	-0.73	-380.13%	―	―	54.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRAW	49 Neutral	$10.15M	0.07	7432.32%	―	1159.29%	―
LSTA	48 Neutral	$18.35M	-1.00	-71.45%	―	―	15.32%

Traws Pharma Corporate Events

Traws Pharma advances flu and COVID-19 antiviral pipeline

On January 13, 2026, Traws Pharma filed a U.S. Investigational New Drug application with the FDA for tivoxavir marboxil (TXM), a potential best-in-class, single-dose oral CAP-dependent endonuclease inhibitor for the treatment of seasonal and avian influenza, a move that represents the final step toward formal consideration by BARDA for inclusion in the U.S. strategic national stockpile. In a separate update from an ongoing randomized Phase 2 trial in mild-to-moderate COVID-19, the company reported interim data in 50 patients showing that ratutrelvir, its ritonavir-free oral 3CL protease inhibitor, delivered faster sustained symptom resolution than PAXLOVID, no observed viral or symptom rebound events, fewer adverse effects and favorable tolerability, including in PAXLOVID-ineligible patients at higher risk of severe disease, reinforcing Traws’ bid to position ratutrelvir as a next-generation COVID-19 therapy and to expand its role in both acute treatment and potential long-COVID prevention strategies.

The most recent analyst rating on (TRAW) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Reports Positive Phase 2 Trial Results

Traws Pharma announced positive interim results from a Phase 2 trial of ratutrelvir, a ritonavir-free oral COVID-19 treatment, on December 17, 2025. The data highlighted a favorable safety profile, no viral rebounds, and potential benefits for patients ineligible for Paxlovid due to contraindications, as well as its potential role in Long COVID prevention. With a differentiated clinical profile, this investigational treatment positions Traws Pharma as a key contender in the multi-billion-dollar COVID-19 therapeutic market.

The most recent analyst rating on (TRAW) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Approves Executive Stock Options

On December 12, 2025, Traws Pharma‘s Compensation Committee approved stock options and restricted stock units for its executive officers. This decision, under the 2021 Incentive Compensation Plan, aims to incentivize key leaders, potentially impacting the company’s operational focus and market positioning.

The most recent analyst rating on (TRAW) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Holds Virtual Annual Meeting 2025

On November 21, 2025, Traws Pharma held its Annual Meeting virtually, with 48% of its outstanding shares represented. During the meeting, stockholders elected seven directors, approved amendments to the 2021 Incentive Compensation Plan, and ratified KPMG LLP as the independent auditor for 2025. Additionally, it was decided that advisory votes on executive compensation will occur every two years, with the next vote scheduled for the 2027 Annual Meeting.

Traws Pharma Reports Q3 2025 Financial Results

On November 13, 2025, Traws Pharma announced its financial results for the quarter ending September 30, 2025, highlighting significant cost reductions and the acquisition of intellectual property assets. The company is advancing its Phase 2 studies for ratutrelvir, a potential COVID-19 therapy, and tivoxavir marboxil for bird flu and seasonal flu, both representing substantial market opportunities. The company also reported management updates and a decrease in net loss compared to the previous year, indicating a strategic shift towards antiviral programs and partnerships for legacy oncology assets.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Approves Executive Stock Options Grant

On October 12, 2025, Traws Pharma‘s Compensation Committee approved stock options for its executive officers, with a total of 184,492 options granted. The options, priced at $3.01 per share, will vest in one year, enhancing executive retention and aligning management interests with shareholder value.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.